1 Talaei Z,Sheikhbahaei S,Ostadi V,et al.Recurrent vulvovaginal candidiasis:could it be related to cell-mediated immunity defect in response to candida antigen?.Int J Fertil Steril,2017,11:134-141. 2 段渭云,王冬梅,史志艳.复发性外阴阴道假丝酵母菌病发病危险因素与治疗分析.海南医学,2017,28:3475-3478. 3 Junko Y,Palmer GE,Eberle KE,et al.Vaginal Epithelial Cell-Derived S100 Alarmins induced by candida albicans via pattern recognition receptor interactions are sufficient but not necessary for the acute neutrophil response during experimental vaginal candidiasis.Infect Immun,2014,82:783-792. 4 Yano J,Noverr MC,Fidel PL,et al.Vaginal heparan sulfate linked to neutrophil dysfunction in the acute inflammatory response associated with experimental vulvovaginal candidiasis.mBio,2017,8:e00211-17. 5 Hammad NM,El BNE,Nasr AM,et al.Mannose-Binding lectin gene polymorphism and its association with susceptibility to recurrent vulvovaginal candidiasis.Biomed Res Int,2018,2018:1-8. 6 Namarta K,Jatinder S,Sujata S,et al.Genetic and phenotypic screening of mannose-binding lectin in relation to risk of recurrent vulvovaginal infections in women of north India:A Prospective Cohort Study.Front Microbiol,2017,8:1-14. 7 Babula O,Gunta Lazdāne,Kroica J,et al.Frequency of interleukin-4 (il-4) -589 gene polymorphism and vaginal concentrations of il-4,nitric oxide,and mannose-binding lectin in women with recurrent vulvovaginal candidiasis.Clin Infect Dis,2005,40:1258-1262. 8 Rosentul DC,Delsing CE,Jaeger M,et al.Gene polymorphisms in pattern recognition receptors and susceptibility to idiopathic recurrent vulvovaginal candidiasis.Front Microbiol,2014,5:1-7. 9 Zahedi N,Kenari SA,Mohseni S,et al.Is human Dectin-1 Y238X gene polymorphism related to susceptibility to recurrent vulvovaginal candidiasis? Curr Med Mycol,2016,2:15-19. 10 Jaeger M,Carvalho A,Cunha C,et al.Association of a variable number tandem repeat in theNLRP3gene in women with susceptibility to RVVC.Eur J Clin Microbiol Infect Dis,2016,35:797-801. 11 Luca AD,Carvalho A,Cunha C,et al.IL-22 and IDO1 affect immunity and tolerance to murine and human vaginal candidiasis.PLoS Pathog,2013,9:e1003486. 12 Neves NA,Carvalho LP,Antnio Carlos V Lopes,et al.Successful treatment of refractory recurrent vaginal candidiasis with cetirizine plus fluconazole.J Low Genit Tract Dis,2005,9:167-170. 13 White D,Vanthuyne A,Wood P,et al.Zafirlukast for severe recurrent vulvovaginal candidiasis:An open label pilot study.Sex Transm Infect,2004,80:219-222. 14 De Araújo Eliseu Frank,Claudia F,Lima G N A D,et al.The IDO-AhR axis controls Th17/Treg immunity in a pulmonary model of fungal infection.Front Immunol,2017,8:880-895. 15 梁轶珩,刘小平,樊尚荣,等.白细胞介素17A等细胞因子在复发性外阴阴道假丝酵母菌病发病中的作用.现代妇产科进展,2018,27:430-433+438. 16 Van de Wijgert JH,Borgdorff H,Verhelst R,et al.The vaginal microbiota:What have we learned after a decade of molecular characterization?.PLoS One,2014,9:e105998. 17 Rocha-Ramírez LM,Pérez-Solano RA,Casta?ón-Alonso SL,et al.Probiotic lactobacillus strains stimulate the inflammatory response and activate human macrophages.J Immunol Res,2017,2017:1-14. 18 Donnarumma G,Molinaro A,Cimini D,et al.Lactobacillus crispatus L1:High cell density cultivation and exopolysaccharide structure characterization to highlight potentially beneficial effects against vaginal pathogens.BMC Microbiol,2014,14:137. 19 李军英.观察微生态制剂对复发性念珠菌性外阴阴道炎治疗效果的影响.当代医学,2016,22:141-142. 20 Vieirabaptista P,Donders G.Is it possible to prevent recurrent vulvovaginitis? The role of Lactobacillus plantarum I1001 (CECT7504).Eur J Clin Microbiol Infect Dis,2016,36:1701-8. 21 陆一纶,吴岚,唐若愚,等.白念珠菌毒力因子及致病机制研究进展.中国真菌学杂志,2018,13:101-104. 22 Wan TGH,Antonio RCJ,Norman P.The Elusive Anti-Candida Vaccine:Lessons from the past and opportunities for the future.Front Immunol,2018,9:897-910. 23 Bonfim-Mendon?a Patrícia,Isis C,Tobaldini-valerio flávia,et al.overview of β-glucans from laminaria spp.:Immunomodulation properties and applications on biologic models.Int J Mol Sci,2017,18:1629-1650. 24 Edwards JE J,Schwartz M,Schmidt C,et al.A Fungal Immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis-a phase 2 randomized,double-blind,placebo-controlled trial.Clin Infect Dis,2018,66:1928-1936. 25 Uppuluri P,Singh S,Alqarihi A,et al.Human anti-als3p antibodies are surrogate markers of ndv-3a vaccine efficacy against recurrent vulvovaginal candidiasis.Front Immunol,2018,9:1349-1359. 26 De Bernardis F,Arancia S,Sandini S,et al.Studies of immune responses in candida vaginitis.Pathogens,2015,4:697-707.
